SCHEMBL2233095

SCHEMBL2233095

c1ccc(N(c2ccccc2)c2ccc(-c3cc4c(s3)c3cc(-c5ccc(N(c6ccccc6)c6ccccc6)cc5)sc3c3cc(-c5ccc(N(c6ccccc6)c6ccccc6)cc5)sc43)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.47
CYP1A1 P04798 3/20 0.41
CYP1B1 Q16678 3/20 0.41
ALDH1A1 P00352 5/20 0.41
MAPT P10636 3/20 0.41
CYP1A2 P05177 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
PTP4A3 O75365 1/20 0.40
PTP4A2 Q12974 1/20 0.40
PTP4A1 Q93096 1/20 0.40
ADORA2A P29274 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24369567 0.87 CYP1A1 (0.41) APPCYP1A1CYP1B1ALDH1A1MAPT
SCHEMBL24368533 0.86 CYP1A1 (0.44) APPCYP1A1CYP1B1ALDH1A1MAPT
SCHEMBL24368534 0.86 CYP1A1 (0.44) APPCYP1A1CYP1B1ALDH1A1MAPT
SCHEMBL24368570 0.86 CYP1A1 (0.44) APPCYP1A1CYP1B1ALDH1A1MAPT
SCHEMBL24368540 0.86 CYP1A1 (0.44) APPCYP1A1CYP1B1ALDH1A1MAPT
SCHEMBL24369566 0.86 CYP1A1 (0.44) APPCYP1A1CYP1B1ALDH1A1MAPT
SCHEMBL2234404 0.85 CYP1A1 (0.47) APPCYP1A1CYP1B1MAPTCYP1A2
SCHEMBL12345731 0.84 JAK2 (0.40) APPALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL11966157 0.84 APP (0.46) APPCYP1A1CYP1B1ALDH1A1MAPT
SCHEMBL23337582 0.82 CYP1A1 (0.51) CYP1A1CYP1B1ALDH1A1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2361915-B1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF NIPPON KAYAKU KK (JP) 2015-01-28 EP disclosed
EP-2361915-B1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF NIPPON KAYAKU KK (JP) 2015-01-28 EP disclosed
US-8313671-B2 Heterocyclic compound and use thereof HIROSHIMA UNIVERSITY (JP) 2012-11-20 US disclosed
US-8313671-B2 Heterocyclic compound and use thereof HIROSHIMA UNIVERSITY (JP) 2012-11-20 US disclosed
US-8313671-B2 Heterocyclic compound and use thereof HIROSHIMA UNIVERSITY (JP) 2012-11-20 US disclosed
EP-2361915-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF Hiroshima University (JP) 2011-08-31 EP disclosed
US-20110204295-A1 Novel Heterocyclic Compound And Use Thereof HIROSHIMA UNIVERSITY (JP) 2011-08-25 US disclosed
US-20110204295-A1 Novel Heterocyclic Compound And Use Thereof HIROSHIMA UNIVERSITY (JP) 2011-08-25 US disclosed
US-20110204295-A1 Novel Heterocyclic Compound And Use Thereof HIROSHIMA UNIVERSITY (JP) 2011-08-25 US disclosed
WO-2010058833-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF 国立大学法人広島大学 (JP) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110204295-A1 Novel Heterocyclic Compound And Use Thereof SCLY, C9, C1S APP 2561/4885CYP1A1 119/4885CYP1B1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.